

Special Issue

Novel Targets of Drug Monitoring for Antibiotics

Message from the Guest Editor

Drug monitoring is crucial to successfully curing patients' infections, as typified by vancomycin. Just over 20 years ago, target concentration intervention (TCI) was distinguished from therapeutic drug monitoring (TDM). Both TCI and TDM can be considered as approaches to concentration-controlled dosing of individual patients (Holford, 1999). Therapeutic drug monitoring (TDM) is a branch of clinical chemistry and clinical pharmacology that specializes in the measurement of medication concentrations in blood. On the other hand, target concentration intervention (TCI) embraces pharmacokinetic and pharmacodynamic concepts and uses the idea of a target effect and associated target concentration to make rational individual dose decisions. This Special Issue aims to publish high-quality manuscripts evaluating the novel target of drug monitoring for antibiotics. In the era of individualized medicine, further research of the safety and efficacy of drug monitoring of antibiotics based on novel targets (e.g., unbound drug concentration, metabolites and/or biomarkers) is warranted.

Guest Editor

Prof. Dr. Yasuhiro Tsuji

Laboratory of Clinical Pharmacometrics, Nihon University, Chiba 274-8555, Japan

Deadline for manuscript submissions

closed (15 April 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/59667

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)